Reliance Industries Limited (RIL) informed today that it has collaborated with BP, one of the world's seven oil & gas ‘supermajors’ and British multinational company to commence production from the Satellite Cluster Gas Field in block KG D6, off the east coast of India.  

Biocon Limited’s subsidiary Biocon Biologics Ltd has informed the bourses that Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. has received marketing authorisation approval from European Commission (EC), following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. 

The company today announced that it has applied to Central Drugs Standard Control Organisation (CDSCO) of India for the approval of phase 3 clinical trials of ‘Molnupiravir’ capsules, which have shown promising results during the treatment of COVID-19 positive patient. 

We follow a ‘growth at a reasonable price (GARP) investing style’ since it combines the best of both worlds. We have identified themes that provide secular growth opportunities such as private banks, unorganised to organised, speciality chemicals, manufacturing in India, and technology/digital.

Canara Robeco has launched its Canara Robeco Focused Equity Fund and is currently opened for subscription. Read onto find out more about it.

Following the global trend of medication shifting from allopathy to herbal therapy in veterinary, Hester Biosciences announced on Saturday that it has embarked on a journey to produce research-based herbal products for livestock and poultry.  

How should investors evaluate a company while considering an investing in the company's stock? Read on to find out more.

SEBI registered investment advisers (RIAs) do promote direct plans in mutual funds a lot. So, does it make sense to invest in direct plans via them? Let’s find out.

The most important market moving news for the week ending April 23, 2021.

Caplin Steriles Limited, a subsidiary company of Caplin Point Laboratories Limited announced this morning that it has been granted approval from USFDA for its abbreviated new drug application (ANDA) Prochlorperazine Edisylate injection USP, 10 mg/2 ml (5 mg/ml) vials presentations.